@heatherhirschmd's testosterone claims for women, checked

What did @heatherhirschmd actually say?

The core claim is this: if you already have acne or hair thinning and your testosterone is low, those symptoms are probably not caused by androgens, and you would still be a good candidate for low-dose transdermal testosterone. She also argues that post-menopausal women can sometimes have elevated testosterone as a stress response, driven by the adrenal glands compensating for ovarian estrogen loss.

She recommends testosterone gels like AndroGel or Testim over pellets or injections, citing the ability to titrate the dose. She frames low testosterone, roughly under 20-25 ng/dL, as a threshold for candidacy, while acknowledging there is no hard cutoff. Her sign-off: "Start low and slow."

Does the science back this up?

Mostly, yes, though with some important caveats. The reasoning that low testosterone makes androgen-driven acne less likely is biologically sound, but it is not as clean as the video implies. Acne and androgenic alopecia are also influenced by androgen sensitivity at the tissue level, not just circulating testosterone concentrations.

On the adrenal compensation claim: the hypothalamic-pituitary-adrenal axis does become more active in response to menopause-related hormonal shifts, and DHEA, an adrenal androgen precursor, can be converted peripherally to testosterone and estrogen. However, the video's framing of the brain "going to the adrenal glands" for estrogen and getting testosterone and cortisol instead is a significant simplification. Adrenal androgen secretion in post-menopausal women is real but not primarily a cortisol-equivalent stress response to estrogen deficiency. Labrie et al. (2003, Journal of Steroid Biochemistry and Molecular Biology) documented peripheral conversion of adrenal androgens extensively, but the mechanism is more nuanced than described here.

On transdermal preference: the Endocrine Society and the Menopause Society do not have approved testosterone formulations for women in most countries, but clinical guidance consistently favors transdermal delivery for dose control, which she correctly states (Islam et al., 2019, Therapeutic Advances in Endocrinology and Metabolism).

What did they get wrong (or right)?

She gets the clinical logic mostly right. Low circulating testosterone does reduce the probability that acne or hair thinning is androgen-mediated, and that is a reasonable point to make to women who are hesitant about testosterone therapy. Credit where it is due.

What she oversimplifies is the androgen sensitivity piece. Conditions like polycystic ovary syndrome have taught us that women can have significant androgen-driven acne with normal or low serum testosterone, because the issue is often at the receptor level or due to elevated DHT, not total testosterone (Carmina and Lobo, 2003, Fertility and Sterility). A low testosterone number does not fully exclude androgen-driven symptoms. Her framing, "if it was androgen driven, it would probably be your testosterone levels would be high," is not always true.

Her adrenal explanation is memorable but mechanistically loose. Cortisol is not a sex steroid. Grouping cortisol with testosterone as "sex steroids" that "look very similar" because they are both steroids is the kind of shorthand that sounds plausible but will mislead anyone who takes it literally. All steroids share a backbone, but their functions and receptors are distinct.

Her recommendation to avoid pellets and injections because levels can go too high and stay elevated is well-supported. Dumesic et al. (2021, Journal of Clinical Endocrinology and Metabolism) documented that testosterone pellets in women frequently result in supraphysiologic levels that persist for months.

What should you actually know?

The big picture here is reasonable: women with genuinely low testosterone who have mild acne or hair thinning should not automatically rule out testosterone therapy out of fear those symptoms will worsen. That is a useful, practical message that often does not get communicated clearly enough.

But there are things this video glosses over. First, there are no FDA-approved testosterone formulations for women in the United States. Using AndroGel means using a male-formulated product off-label, at a fraction of the typical male dose. That is common clinical practice but carries its own complexity. Second, serum testosterone measurement in women is notoriously unreliable at low concentrations, and the reference ranges she cites, 2 to 45 ng/dL or 5 to 60, vary significantly by assay and lab. Liquid chromatography-mass spectrometry is the gold standard but not universally used (Rosner et al., 2007, Clinical Chemistry). Third, androgen sensitivity at the hair follicle and sebaceous gland level matters as much as serum levels. A baseline assessment before and regular monitoring after starting therapy is more important than a single lab value as a candidacy check.

• Low serum testosterone reduces the likelihood of androgen-driven acne, but does not eliminate it entirely due to tissue-level androgen sensitivity.
• Transdermal testosterone allows dose titration and is preferred over pellets or injections in women, per clinical guidance.
• Adrenal androgens do increase in relative importance after menopause, but the mechanism is more complex than the video describes.
• No FDA-approved testosterone product exists for women in the US; off-label use of male-formulated gels is common.
• Testosterone assays at low female ranges are often unreliable; reference ranges differ by lab and method.